Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges
(2011) Vaccine — Vol. 29, n° 16, p. 2856-2864 (2011)
Files
HanquetGetalVaccine2011.pdf
Restricted Access - Adobe PDF
- 384.51 KB
Details
- Authors
- Abstract
- In Belgium, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the national schedule in 2007. The early impact of PCV7 vaccination on paediatric invasive disease was estimated by comparing pre- and post-vaccination incidence from national surveillance. In children <2 year-olds, vaccine-serotype incidence declined by 96% but non-vaccine-types increased 2-3-fold. Overall invasive disease decreased by 23-46%, depending on adjustment for under-reporting and pre-vaccine trends. Non-vaccine-types 1 and 19A had increased before PCV7 use, suggesting the contribution of other factors. Estimation of PCV7 impact comparing pre- and post-vaccination data should adjust for pre-vaccine trends, and serotype dynamics need further exploration. © 2011 Elsevier Ltd.
- Affiliations
Citations
Hanquet, G., Lernout, T., Vergison, A., Verhaegen, J., Kissling, E., Tuerlinckx, D., Malfroot, A., Swennen, B., & Sabbe, M. (2011). Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges. Vaccine, 29(16), 2856-2864. https://doi.org/10.1016/j.vaccine.2011.02.016 (Original work published 2011)